本帖最后由 老马 于 2012-1-13 21:20 编辑 5 A# {' p" U( v5 Z3 R2 w
( z$ O, w3 P) i- l: N爱必妥和阿瓦斯丁的比较
1 u, \, q" d: X/ p
& o$ j- B8 |2 W: a# ^# Thttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/7 A0 v: Z$ e& `/ `/ T$ T
4 i2 x0 {$ U+ r2 P1 K4 u
% m% i- t; |7 c/ c
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/6 F! K9 o1 f4 N* Y$ n6 P& x" \
==================================================& X# F* T5 g( ?% A
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)" ]9 ^% o, g% y/ E( W
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) \. r6 B/ a6 O" cResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.8 O9 y* X7 w. j" I6 ^' a& I8 Z$ ?3 R
|